tiprankstipranks
Advertisement
Advertisement

JSPR Stock Latest News

Jasper Therapeutics Completes Kira Pharmaceuticals Acquisition, Issues CVRs
Company AnnouncementsJasper Therapeutics Completes Kira Pharmaceuticals Acquisition, Issues CVRs
3d ago
8K
JSPR
Jasper Therapeutics Completes Kira Acquisition and PIPE Financing
PremiumCompany Announcements
Jasper Therapeutics Completes Kira Acquisition and PIPE Financing
17d ago
8K
JSPR
Jasper Therapeutics acquires Kira, extends cash runway
PremiumCompany Announcements
Jasper Therapeutics acquires Kira, extends cash runway
17d ago
8K
JSPR
Jasper Therapeutics trading resumes
PremiumThe Fly
Jasper Therapeutics trading resumes
18d ago
JSPR
Jasper Therapeutics completes acquisition of Kira Pharmaceuticals
PremiumThe Fly
Jasper Therapeutics completes acquisition of Kira Pharmaceuticals
18d ago
JSPR
Jasper Therapeutics trading halted, news pending
PremiumThe FlyJasper Therapeutics trading halted, news pending
18d ago
JSPR
Jasper Therapeutics Receives Nasdaq Minimum Bid Price Notice
Premium
Company Announcements
Jasper Therapeutics Receives Nasdaq Minimum Bid Price Notice
2M ago
8K
JSPR
Jasper Therapeutics Launches Strategic Alternatives Review Amid Uncertainty
Premium
Company Announcements
Jasper Therapeutics Launches Strategic Alternatives Review Amid Uncertainty
2M ago
8K
JSPR
Jasper Therapeutics initiates review of strategic alternatives
PremiumThe Fly
Jasper Therapeutics initiates review of strategic alternatives
2M ago
JSPR
Jasper Therapeutics Announces Board Resignation and Committee Change
PremiumCompany Announcements
Jasper Therapeutics Announces Board Resignation and Committee Change
2M ago
8K
JSPR
Cisco, Arista, Jasper, StoneCo, Lisata Trending With Analysts
PremiumWeekend Updates
Cisco, Arista, Jasper, StoneCo, Lisata Trending With Analysts
3M ago
ANET
CSCO
Jasper Therapeutics price target lowered to $3 from $4 at RBC Capital
PremiumThe Fly
Jasper Therapeutics price target lowered to $3 from $4 at RBC Capital
3M ago
JSPR
Jasper Therapeutics downgraded to Hold from Buy at TD Cowen
PremiumThe FlyJasper Therapeutics downgraded to Hold from Buy at TD Cowen
3M ago
JSPR
Jasper Therapeutics price target lowered to $7 from $12 at Evercore ISI
Premium
The Fly
Jasper Therapeutics price target lowered to $7 from $12 at Evercore ISI
4M ago
JSPR
Jasper Therapeutics’ Deep Cuts May Backfire: Analyst Warns Downsizing Could Undermine Briquilimab Strategy and Cash Runway
Premium
Company Announcements
Jasper Therapeutics’ Deep Cuts May Backfire: Analyst Warns Downsizing Could Undermine Briquilimab Strategy and Cash Runway
4M ago
JSPR
Buy Rating on Jasper: Briquilimab’s Strong CSU Efficacy, Favorable Safety, and Competitive Profile Underpin Key Near‑Term Value Driver
PremiumRatings
Buy Rating on Jasper: Briquilimab’s Strong CSU Efficacy, Favorable Safety, and Competitive Profile Underpin Key Near‑Term Value Driver
4M ago
JSPR
Jasper Therapeutics reports Q4 EPS (32c), consensus (82c)
PremiumThe Fly
Jasper Therapeutics reports Q4 EPS (32c), consensus (82c)
4M ago
JSPR
Jasper Therapeutics assumed with a Neutral at UBS
PremiumThe Fly
Jasper Therapeutics assumed with a Neutral at UBS
4M ago
JSPR
Jasper Therapeutics, Inc. (JSPR) Q4 Earnings Cheat Sheet
PremiumPre-Earnings
Jasper Therapeutics, Inc. (JSPR) Q4 Earnings Cheat Sheet
5M ago
JSPR
Jasper Therapeutics initiated with a Buy at Rodman & Renshaw
PremiumThe FlyJasper Therapeutics initiated with a Buy at Rodman & Renshaw
7M ago
JSPR
Briquilimab’s Robust Efficacy and Favorable Safety in Urticaria Indicate Strong Upside for Jasper Therapeutics and Support a Buy Rating
Premium
Ratings
Briquilimab’s Robust Efficacy and Favorable Safety in Urticaria Indicate Strong Upside for Jasper Therapeutics and Support a Buy Rating
7M ago
JSPR
Jasper Therapeutics Reports Strong Briquilimab Data in Urticaria
Premium
Company Announcements
Jasper Therapeutics Reports Strong Briquilimab Data in Urticaria
7M ago
8K
JSPR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >